neoadjuvant immunotherapy
Showing 1 - 5 of 5
Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)
Recruiting
- Neoadjuvant Immunotherapy
-
Tianjin, ChinaThe Second Hospital of Tianjin Medical University
Apr 20, 2023
Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)
Recruiting
- Esophageal Carcinoma
- Neoadjuvant Immunotherapy
- PD-1 blockade
- +2 more
-
Beijing, Beijing, ChinaQin li
Mar 8, 2023
Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy Trial (radical surgery after
Not yet recruiting
- Advanced Gastric Carcinoma
- +2 more
- radical surgery after neoadjuvant immunotherapy
- radical surgery after neoadjuvant chemotherapy
- (no location specified)
Feb 26, 2022
Gastric Cancer, Magnetic Resonance Imaging, Tomography, X-Ray Computed Trial (PD-1 inhibitor)
Not yet recruiting
- Gastric Cancer
- +4 more
- PD-1 inhibitor
- (no location specified)
May 30, 2021
Ovarian Cancer, Neoadjuvant Chemo, Anti-PD-1 Trial in Hangzhou (BGB-A317, albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5)
Recruiting
- Ovarian Cancer
- +3 more
- BGB-A317
- albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital of Zhejiang University School of Medi
Mar 23, 2021